SynAgile Corporation Announces Positive Phase 2 Top Line Results for DopaFuse® Levodopa-Carbidopa Delivery System
November 04, 2022 01:52 ET | SynAgile Corporation
SAN JOSE, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation ( today announced positive results from its Phase 2 clinical trial of continuous levodopa-carbidopa (LD-CD)...
DopaFuse Delivery System
SynAgile Completes Enrollment of its Phase 2 Clinical Trial of its DopaFuse Delivery System
September 01, 2022 00:52 ET | SynAgile Corporation
SAN JOSE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation ( is pleased to announce it has completed enrollment of its clinical trial evaluating the DopaFuse Delivery...
DopaFuse Delivery System
First Patient Treated with the DopaFuse® Delivery System
October 27, 2021 02:58 ET | SynAgile Corporation
WILSON, Wyo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa)...
Logo_300pxX100px can edit.png
SynAgile Corporation Announces Closing of Financing, Appointment of Mr. Michael McNamara to the Board of Directors, and Appointment of Dr. C. Warren Olanow as Chief Medical Officer
September 22, 2021 01:22 ET | SynAgile Corporation
WILSON, Wyoming, Sept. 22, 2021 (GLOBE NEWSWIRE) -- SynAgile Corporation (, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its...